SCHEDULE: Adage Capital Discloses 2.26% Stake in Tango Therapeutics

Adage Capital Management and its principals reported a passive 2.26% beneficial ownership stake in Tango Therapeutics, Inc. as of September 30, 2025.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 2,511,000 shares of Tango Therapeutics, Inc. Common Stock.
• This ownership represents 2.26% of the company's outstanding Common Stock.
• The percentage is calculated based on 111,260,247 shares outstanding as of July 29, 2025, as reported in Tango Therapeutics' Form 10-Q for the quarter ended June 30, 2025.
• The reporting persons hold shared voting and shared dispositive power over all 2,511,000 shares.
• The investment is stated to be acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The disclosure of a passive institutional stake by a reputable firm like Adage Capital Management is generally viewed favorably, signaling investor confidence in the company. However, it is a routine disclosure and does not provide new operational or financial performance information.

Positives

• The disclosure of a significant passive stake by an institutional investor like Adage Capital Management can be viewed as a vote of confidence in Tango Therapeutics' long-term prospects.
• The investment is held in the ordinary course of business, indicating a standard portfolio allocation rather than an activist intent.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Tango Therapeutics, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This Schedule 13G filing indicates a passive investment by a prominent institutional asset manager in Tango Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector, where institutional investors often take positions in companies with promising drug pipelines or technological platforms. The 2.26% stake suggests a portfolio allocation rather than an attempt to influence corporate strategy, which is typical for passive institutional investments below the 5% threshold for Schedule 13D filings.

Comparison to Industry Standards

• Adage Capital Management is a well-known hedge fund, and its investment in Tango Therapeutics aligns with typical institutional investment strategies in the biotech sector, often targeting companies with high growth potential or innovative therapies.
• A 2.26% stake is a standard passive position for institutional investors, indicating confidence in the company's fundamentals without seeking active control, similar to how other large funds might hold stakes in comparable early-to-mid-stage biotech firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence among existing shareholders and potentially attract new investors, as it signals external validation of the company's value proposition.
• Company Management: While a passive stake, it indicates that institutional capital is invested in the company, which can be a positive signal for management regarding market perception and potential future capital access.

Key Dates

Keywords

Tango Therapeutics, Adage Capital Management, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Biotechnology, Investment Management